<DOC>
	<DOC>NCT00384605</DOC>
	<brief_summary>A 1 year worldwide study in obese and overweight patients to assess the safety and effect on body weight of an investigational weight loss drug.</brief_summary>
	<brief_title>An Investigational Drug Study to Assess Weight Loss in Obese and Overweight Patients (0364-037)(TERMINATED)</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<criteria>Male or female, 18 years of age or older, with Body Mass Index (BMI) between 30 kg/m2 and 43 kg/m2, inclusive (BMI between 27 kg/m2 and 43 kg/m2, inclusive, for those with obesityrelated comorbidities). Obesityrelated comorbidities associated with a BMI of 27 kg/m2 or higher include hypertension, dyslipidemia or sleep apnea Stable weight (+/3 kg) for at least 3 months prior to study start History of diabetes mellitis, major psychiatric disorder, significant cardiovascular disease, stroke, TIA, neurological disorder, nonfebrile seizures Screening systolic blood pressure &gt; 160 mm Hg or diastolic blood pressure &gt; 100 mm Hg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>